Therapeutic effect of varied fractionated radiotherapy for bone metastases from primary liver cancer: a prospective randomized multiple centres clinical trail

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000967

Enrollment

Unknown

Registered

2009-11-13

Start date

2009-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastases from primary liver cancer

Interventions

1. Conventional fractionated iiradiation group:40-54Gy in 20-27 fractions of 2 Gy/fraction, 5 times a week

2. Hypo-fractionated irradiation group:20-28Gy in 5-7 fractions of 4 Gy/fraction, 1 time per day. (EBD=40-54Gy)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The primary HCC patients diagnosed by clinical imageology, medical history or histopathology with bone metastases or accompanying soft-tissue mass comfirmed in CT, MRI or SPECT-CT; 2. Age arrage from 18 to 85years, KPS more than 40 scores, withour contraindication of radiotherapy such as dysfunction of important organs, active bleeding and tubercle; 3. Understanding and writing informed consent regarding this trail; 4. without other tumors.

Exclusion criteria

Exclusion criteria: 1. With internal radiotherapy using isotope or chemotherapy before external beam radiotherapy; 2. Pregnant or lactation women; 3. Acute infection or other serious potential affections; 4. Obvious neurological, psychiatric history, including dementia impacting the comprehension and imformed consent.

Design outcomes

Primary

Measure	Time frame
the intensity of pain;	—

Countries

China

Contacts

Public ContactHe Jian

he.jian@zs-hospital.com+86 13386057161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026